{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:19Z","timestamp":1788866899118,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lions research fund","award":["BKV-2022-00046"],"award-info":[{"award-number":["BKV-2022-00046"]}]},{"name":"Joanna Cocozza Foundation for Children's Medical Research"},{"name":"Link\u00f6ping University Cancer Network"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["project 20 1231 PJF"],"award-info":[{"award-number":["project 20 1231 PJF"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>T-cell acute lymphoblastic leukaemia (T-ALL) exhibits exceptionally high levels of DNA methylation, with silencing of the DNA demethylating enzyme <jats:italic>TET2<\/jats:italic> implicated in T-ALL\u2019s hypermethylation phenotype. We propose that DNA hypomethylating agents (HMAs) could be particularly potent in T-ALL cells with this phenotype. Here, we used a reversible DNMT1-specific inhibitor and the conventional HMAs, 5-azacytidine and decitabine, to assess the effects of global DNA methylation loss in T-ALL cell lines and the potential of using HMAs as targeted therapeutic agents in T-ALL. We demonstrate that removal of DNA methylation, even in the absence of DNA damage, results in cell death and that toxicity is negatively correlated with methylation levels. Notably, whereas DNA demethylation caused limited transcriptional changes, key tumour suppressor genes, including <jats:italic>TET2<\/jats:italic>, were upregulated in a methylation-dependent manner. Few endogenous retroviruses or immune-related genes were reactivated after demethylation, challenging the contribution of \u2018viral mimicry\u2019 to HMA toxicity. Together, these findings provide fundamental insights into the role of DNA methylation in T-ALL, demonstrating that the removal of DNA methylation alone is sufficient to (i) induce cell death in T-ALL cell lines and (ii) reactivate\u00a0silenced tumour suppressor genes. Our findings support the development of therapies targeting the unique methylation phenotype of T-ALL.<\/jats:p>","DOI":"10.1186\/s13148-025-01915-y","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:10:18Z","timestamp":1751533818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exposing the DNA methylation-responsive compartment of the leukaemic genome in T-ALL cell lines support its potential as a novel therapeutic target in T-ALL"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2395-6083","authenticated-orcid":false,"given":"Maike","family":"Bensberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9580-4455","authenticated-orcid":false,"given":"Aida","family":"Selimovi\u0107-Pa\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8369-0731","authenticated-orcid":false,"given":"Lisa","family":"Haglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8713-7434","authenticated-orcid":false,"given":"Sandra","family":"Hellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-1769","authenticated-orcid":false,"given":"Colm E.","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"11","key":"1915_CR1","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","volume":"38","author":"SR Rheingold","year":"2024","unstructured":"Rheingold SR, Bhojwani D, Ji L, Xu X, Devidas M, Kairalla JA, et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia. 2024;38(11):2382\u201394.","journal-title":"Leukemia"},{"issue":"8","key":"1915_CR2","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794\u2013803.","journal-title":"Cancer"},{"issue":"10","key":"1915_CR3","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429\u201340.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1915_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","volume":"11","author":"SR Bohl","year":"2018","unstructured":"Bohl SR, Bullinger L, Rucker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11(5):361\u201371.","journal-title":"Expert Rev Hematol"},{"issue":"34","key":"1915_CR5","doi-asserted-by":"publisher","first-page":"e2110758118","DOI":"10.1073\/pnas.2110758118","volume":"118","author":"M Bensberg","year":"2021","unstructured":"Bensberg M, Rundquist O, Selimovic A, Lagerwall C, Benson M, Gustafsson M, et al. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2021;118(34):e2110758118.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"1915_CR6","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s43018-022-00370-5","volume":"3","author":"S Hetzel","year":"2022","unstructured":"Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, et al. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022;3(6):768\u201382.","journal-title":"Nat Cancer"},{"issue":"595","key":"1915_CR7","doi-asserted-by":"publisher","first-page":"eabc4834","DOI":"10.1126\/scitranslmed.abc4834","volume":"13","author":"A Touzart","year":"2021","unstructured":"Touzart A, Mayakonda A, Smith C, Hey J, Toth R, Cieslak A, et al. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Sci Transl Med. 2021;13(595):eabc4834.","journal-title":"Sci Transl Med."},{"issue":"1","key":"1915_CR8","first-page":"95","volume":"58","author":"CM Bender","year":"1998","unstructured":"Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2\u2019-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58(1):95\u2013101.","journal-title":"Cancer Res"},{"issue":"7","key":"1915_CR9","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/0008-5472.CAN-05-2481","volume":"66","author":"KM McGarvey","year":"2006","unstructured":"McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 2006;66(7):3541\u20139.","journal-title":"Cancer Res"},{"issue":"3","key":"1915_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5(3):587\u201398.","journal-title":"Oncotarget"},{"issue":"5","key":"1915_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015;162(5):961\u201373.","journal-title":"Cell"},{"issue":"5","key":"1915_CR12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015;162(5):974\u201386.","journal-title":"Cell"},{"issue":"11","key":"1915_CR13","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1158\/2159-8290.CD-21-0506","volume":"11","author":"R Chen","year":"2021","unstructured":"Chen R, Ishak CA, De Carvalho DD. Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. Cancer Discov. 2021;11(11):2707\u201325.","journal-title":"Cancer Discov"},{"issue":"1","key":"1915_CR14","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1038\/s41598-023-32509-4","volume":"13","author":"ABA Laranjeira","year":"2023","unstructured":"Laranjeira ABA, Hollingshead MG, Nguyen D, Kinders RJ, Doroshow JH, Yang SX. DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. Sci Rep. 2023;13(1):5964.","journal-title":"Sci Rep"},{"issue":"1","key":"1915_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8\u201313.","journal-title":"Int J Cancer"},{"issue":"10","key":"1915_CR16","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002\u201317.","journal-title":"Nat Cancer"},{"issue":"1","key":"1915_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13072-021-00429-0","volume":"14","author":"N Azevedo Portilho","year":"2021","unstructured":"Azevedo Portilho N, Saini D, Hossain I, Sirois J, Moraes C, Pastor WA. The DNMT1 inhibitor GSK-3484862 mediates global demethylation in murine embryonic stem cells. Epigenetics Chromatin. 2021;14(1):56.","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"1915_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s42003-022-03509-3","volume":"5","author":"AK Wiseman","year":"2022","unstructured":"Wiseman AK, Tiedemann RL, Fan H, Shen H, Madaj Z, McCabe MT, et al. Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1. Commun Biol. 2022;5(1):528.","journal-title":"Commun Biol"},{"issue":"11","key":"1915_CR19","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/bloodadvances.2023011970","volume":"8","author":"S De Coninck","year":"2024","unstructured":"De Coninck S, Roels J, Lintermans B, T\u2019Sas S, Taghon T, Curtis DJ, et al. Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia. Blood Adv. 2024;8(11):2646\u20139.","journal-title":"Blood Adv"},{"issue":"3","key":"1915_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gnh032","volume":"32","author":"AS Yang","year":"2004","unstructured":"Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32(3): e38.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1915_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.biopha.2013.01.004","volume":"67","author":"DY Shin","year":"2013","unstructured":"Shin DY, Sung Kang H, Kim GY, Kim WJ, Yoo YH, Choi YH. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2\/M phase through p53-independent pathway in human cancer cells. Biomed Pharmacother. 2013;67(4):305\u201311.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"1915_CR22","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/1535-7163.MCT-13-0137","volume":"12","author":"S Venturelli","year":"2013","unstructured":"Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2\u2019-deoxycytidine in solid tumor cells. Mol Cancer Ther. 2013;12(10):2226\u201336.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"1915_CR23","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/nar\/gkq187","volume":"38","author":"K Patel","year":"2010","unstructured":"Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2\u2019-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucl Acids Res. 2010;38(13):4313\u201324.","journal-title":"Nucl Acids Res"},{"issue":"10","key":"1915_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nmeth794","volume":"2","author":"L Schermelleh","year":"2005","unstructured":"Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, et al. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods. 2005;2(10):751\u20136.","journal-title":"Nat Methods"},{"issue":"22","key":"1915_CR25","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","volume":"119","author":"J Aimiuwu","year":"2012","unstructured":"Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012;119(22):5229\u201338.","journal-title":"Blood"},{"issue":"21","key":"1915_CR26","doi-asserted-by":"publisher","first-page":"11834","DOI":"10.3390\/ijms222111834","volume":"22","author":"Y Ma","year":"2021","unstructured":"Ma Y, Nenkov M, Schroder DC, Abubrig M, Gassler N, Chen Y. Fibulin 2 Is hypermethylated and suppresses tumor cell proliferation through inhibition of cell adhesion and extracellular matrix genes in non-small cell lung cancer. Int J Mol Sci. 2021;22(21):11834.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"1915_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296\u2013307.","journal-title":"Nat Genet"},{"issue":"5","key":"1915_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.leukres.2010.11.015","volume":"35","author":"G Hutter","year":"2011","unstructured":"Hutter G, Kaiser M, Neumann M, Mossner M, Nowak D, Baldus CD, et al. Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. Leuk Res. 2011;35(5):614\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"1915_CR29","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","volume":"122","author":"P Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3398\u2013406.","journal-title":"J Clin Invest"},{"issue":"1","key":"1915_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13072-018-0182-4","volume":"11","author":"KM O'Neill","year":"2018","unstructured":"O\u2019Neill KM, Irwin RE, Mackin SJ, Thursby SJ, Thakur A, Bertens C, et al. Depletion of DNMT1 in differentiated human cells highlights key classes of sensitive genes and an interplay with polycomb repression. Epigenetics Chromatin. 2018;11(1):12.","journal-title":"Epigenetics Chromatin"},{"issue":"6","key":"1915_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179501","volume":"12","author":"C Siebenkas","year":"2017","unstructured":"Siebenkas C, Chiappinelli KB, Guzzetta AA, Sharma A, Jeschke J, Vatapalli R, et al. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS ONE. 2017;12(6): e0179501.","journal-title":"PLoS ONE"},{"issue":"6705","key":"1915_CR32","doi-asserted-by":"publisher","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","volume":"385","author":"MJ Wu","year":"2024","unstructured":"Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024;385(6705):eadl6173.","journal-title":"Science."},{"issue":"2","key":"1915_CR33","doi-asserted-by":"publisher","first-page":"zcad022","DOI":"10.1093\/narcan\/zcad022","volume":"5","author":"Q Chen","year":"2023","unstructured":"Chen Q, Liu B, Zeng Y, Hwang JW, Dai N, Correa IR Jr, et al. GSK-3484862 targets DNMT1 for degradation in cells. NAR Cancer. 2023;5(2):zcad022.","journal-title":"NAR Cancer."},{"key":"1915_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107328","volume":"207","author":"T Chen","year":"2024","unstructured":"Chen T, Mahdadi S, Vidal M, Desbene-Finck S. Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy. Pharmacol Res. 2024;207: 107328.","journal-title":"Pharmacol Res"},{"issue":"16","key":"1915_CR35","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1093\/hmg\/ddr236","volume":"20","author":"JE Loughery","year":"2011","unstructured":"Loughery JE, Dunne PD, O\u2019Neill KM, Meehan RR, McDaid JR, Walsh CP. DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. Hum Mol Genet. 2011;20(16):3241\u201355.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1915_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200768","volume":"32","author":"A Naik","year":"2024","unstructured":"Naik A, Lattab B, Qasem H, Decock J. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer. Mol Ther Oncol. 2024;32(1): 200768.","journal-title":"Mol Ther Oncol"},{"key":"1915_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101086","volume":"59","author":"A Fehn","year":"2025","unstructured":"Fehn A, von Witzleben A, Grages A, Kors TA, Ezic J, Betzler AC, et al. 5-Aza-2\u2019-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells. Neoplasia. 2025;59: 101086.","journal-title":"Neoplasia"},{"issue":"1","key":"1915_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13148-022-01382-9","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Xiong F, Wu G, Liu W, Chen J, Wang B, et al. Gene body methylation in cancer: molecular mechanisms and clinical applications. Clin Epigenetics. 2022;14(1):154.","journal-title":"Clin Epigenetics"},{"issue":"6697","key":"1915_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/25779","volume":"395","author":"RZ Chen","year":"1998","unstructured":"Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 1998;395(6697):89\u201393.","journal-title":"Nature"},{"issue":"1","key":"1915_CR40","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","volume":"13","author":"N Besselink","year":"2023","unstructured":"Besselink N, Keijer J, Vermeulen C, Boymans S, de Ridder J, van Hoeck A, et al. The genome-wide mutational consequences of DNA hypomethylation. Sci Rep. 2023;13(1):6874.","journal-title":"Sci Rep"},{"issue":"6277","key":"1915_CR41","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1126\/science.aad5497","volume":"351","author":"EB Chuong","year":"2016","unstructured":"Chuong EB, Elde NC, Feschotte C. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. Science. 2016;351(6277):1083\u20137.","journal-title":"Science"},{"issue":"6","key":"1915_CR42","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","volume":"6","author":"T Kiziltepe","year":"2007","unstructured":"Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718\u201327.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1915_CR43","doi-asserted-by":"publisher","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Marechal","year":"2013","unstructured":"Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5(9):a012716.","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"2","key":"1915_CR44","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/MCB.01799-07","volume":"28","author":"SS Palii","year":"2008","unstructured":"Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2\u2019-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008;28(2):752\u201371.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1915_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bcp.2014.03.008","volume":"89","author":"S Imanishi","year":"2014","unstructured":"Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH. Constitutive activation of the ATM\/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. Biochem Pharmacol. 2014;89(3):361\u20139.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"1915_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113098","volume":"42","author":"T Yabushita","year":"2023","unstructured":"Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, et al. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell Rep. 2023;42(9): 113098.","journal-title":"Cell Rep"},{"issue":"10","key":"1915_CR47","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18(10):622\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1915_CR48","doi-asserted-by":"crossref","unstructured":"Wu W, Wu W, Xie X, Li J, Gao Y, Xie L, et al. DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells. Oncogene. 2025.","DOI":"10.1038\/s41388-025-03409-w"},{"issue":"1","key":"1915_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/hmg\/ddq451","volume":"20","author":"K Ha","year":"2011","unstructured":"Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, et al. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet. 2011;20(1):126\u201340.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1915_CR50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2643-3230.BCD-20-0059","volume":"1","author":"J Roels","year":"2020","unstructured":"Roels J, Thenoz M, Szarzynska B, Landfors M, De Coninck S, Demoen L, et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 2020;1(3):274\u201389.","journal-title":"Blood Cancer Discov"},{"key":"1915_CR51","first-page":"6092646","volume":"2018","author":"LT Rahmat","year":"2018","unstructured":"Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN. Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Rep Hematol. 2018;2018:6092646.","journal-title":"Case Rep Hematol"},{"issue":"3","key":"1915_CR52","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14(3):246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"1915_CR53","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/ijms25010484","volume":"25","author":"R Mishra","year":"2023","unstructured":"Mishra R, Zokaei Nikoo M, Veeraballi S, Singh A. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance. Int J Mol Sci. 2023;25(1):484.","journal-title":"Int J Mol Sci."},{"issue":"13","key":"1915_CR54","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, et al. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clin Cancer Res. 2020;26(13):3371\u201383.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1915_CR55","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.18632\/oncotarget.1821","volume":"5","author":"K Maes","year":"2014","unstructured":"Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, et al. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget. 2014;5(10):3115\u201329.","journal-title":"Oncotarget"},{"issue":"1","key":"1915_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13148-022-01329-0","volume":"14","author":"T Aumer","year":"2022","unstructured":"Aumer T, Gremmelmaier CB, Runtsch LS, Pforr JC, Yesiltac GN, Kaiser S, et al. Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line. Clin Epigenetics. 2022;14(1):113.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"1915_CR57","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2012-09-459313","volume":"121","author":"JM Klco","year":"2013","unstructured":"Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013;121(9):1633\u201343.","journal-title":"Blood"},{"issue":"12","key":"1915_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PLoS ONE. 2015;10(12): e0146021.","journal-title":"PLoS ONE"},{"issue":"2","key":"1915_CR59","doi-asserted-by":"publisher","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10(2):giab008.","journal-title":"Gigascience"},{"issue":"6","key":"1915_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841\u20132.","journal-title":"Bioinformatics"},{"issue":"10","key":"1915_CR61","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/gb-2012-13-10-r87","volume":"13","author":"A Akalin","year":"2012","unstructured":"Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A, et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 2012;13(10):R87.","journal-title":"Genome Biol"},{"issue":"1","key":"1915_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"22","key":"1915_CR63","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1093\/bioinformatics\/btv422","volume":"31","author":"Y Jin","year":"2015","unstructured":"Jin Y, Tam OH, Paniagua E, Hammell M. TEtranscripts: a package for including transposable elements in differential expression analysis of RNA-seq datasets. Bioinformatics. 2015;31(22):3593\u20139.","journal-title":"Bioinformatics"},{"issue":"1","key":"1915_CR64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"1","key":"1915_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13059-022-02607-z","volume":"23","author":"L Dressler","year":"2022","unstructured":"Dressler L, Bortolomeazzi M, Keddar MR, Misetic H, Sartini G, Acha-Sagredo A, et al. Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource. Genome Biol. 2022;23(1):35.","journal-title":"Genome Biol"},{"issue":"12","key":"1915_CR66","doi-asserted-by":"publisher","first-page":"e007935","DOI":"10.1136\/jitc-2023-007935","volume":"11","author":"JA Carter","year":"2023","unstructured":"Carter JA, Matta B, Battaglia J, Somerville C, Harris BD, LaPan M, et al. Identification of pan-cancer\/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis. J Immunother Cancer. 2023;11(12):e007935.","journal-title":"J Immunother Cancer."},{"issue":"11","key":"1915_CR67","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1093\/bioinformatics\/bty890","volume":"35","author":"A Jain","year":"2019","unstructured":"Jain A, Tuteja G. TissueEnrich: Tissue-specific gene enrichment analysis. Bioinformatics. 2019;35(11):1966\u20137.","journal-title":"Bioinformatics"},{"issue":"6220","key":"1915_CR68","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","journal-title":"Science"},{"issue":"5","key":"1915_CR69","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01915-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:02:20Z","timestamp":1751536940000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01915-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01915-y","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}